CMTM6-Targeting Gene Therapy Vectors for Checkpoint-Resistant Tumors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current tumor immunotherapy using immune checkpoint blockade and existing gene therapy vectors have low efficacy and response rates, necessitating the development of novel targets and combination therapies, particularly for tumors with low or no PD-L1 expression and those resistant to immune checkpoint antibodies.
Innovation Solution
A gene therapy vector targeting CMTM6 expression, utilizing lentivirus and adeno-associated virus vectors, which downregulates CMTM6 and optionally PD-L1, combined with immune checkpoint antibodies, chemotherapy, or metabolism regulating drugs, to inhibit tumor growth and metastasis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immune checkpoint blockade therapy is used to treat tumors, then T-cell activity regulation is improved, but efficacy and response rate remain relatively low
Solution Approach 1:
The patent segments the therapeutic approach by introducing a novel immune checkpoint target CMTM6 separate from traditional PD-1/PD-L1 and CTLA-4 pathways. This allows independent targeting of CMTM6 through gene therapy vectors (AAV or lentivirus) expressing shRNA or siRNA, thereby segmenting the immune checkpoint blockade strategy into multiple independent pathways that can be combined or used separately to improve overall efficacy and response rates
Solution Approach 2:
The patent creates a composite therapeutic approach by combining gene therapy vectors (AAV or lentivirus) with immunomodulatory sequences (shRNA or siRNA targeting CMTM6) to deliver a multi-component solution. This composite gene therapy construct integrates viral delivery mechanisms with specific RNA interference sequences, creating a novel therapeutic agent that addresses both delivery efficiency and target specificity to overcome limitations of conventional single-modality therapies
2Adaptability or versatility
If existing gene therapy vectors are used for tumor immunotherapy, then treatment approaches are expanded, but effectiveness remains unsatisfactory
Solution Approach 1:
The patent achieves universality by developing gene therapy vectors with broad applicability across multiple tumor types and contexts. The AAV and lentivirus vectors expressing CMTM6-targeting shRNA or siRNA are designed to be universally applicable to various cancers regardless of PD-L1 expression status or immune checkpoint antibody resistance, providing a multi-functional platform that can treat diverse tumor types through a single therapeutic mechanism
Solution Approach 2:
The patent introduces dynamics by creating inducible or regulated expression systems within the gene therapy vectors. The vectors can be designed with inducible promoters or regulatory elements that allow dynamic control of CMTM6 knockdown timing and intensity, enabling adaptation to different treatment phases and tumor responses, thereby improving effectiveness while maintaining versatility across clinical scenarios
3Adaptability or versatility
If common immune checkpoint molecules are targeted in gene therapy, then existing antibody drugs can be combined, but gene therapies show no significant advantages
Solution Approach 1:
The patent introduces CMTM6 as an intermediary target that mediates between conventional immune checkpoint pathways and anti-tumor immunity. By targeting CMTM6 through gene therapy, the patent creates an intermediate layer of immune regulation that works synergistically with but distinct from PD-1/PD-L1 and CTLA-4 pathways, providing a bridging mechanism that enhances combination therapy options while delivering unique therapeutic advantages not achievable through conventional checkpoint blockade alone
4Reliability
If CMTM6 is targeted through gene therapy, then novel therapeutic effects are achieved, but development complexity increases
Solution Approach 1:
The patent employs copying by using well-established viral vector backbones (AAV and lentivirus) that have been extensively characterized and optimized. By copying proven delivery mechanisms and regulatory elements from existing commercial and clinical vectors, the patent simplifies the construction process while maintaining high therapeutic efficacy, avoiding the need to develop entirely new vector systems from scratch
Data Source
AI summary
Disclosed are preparation and anti-tumor application of a gene therapy vector interfering CKLF-like MARVEL transmembrane domain-containing protein 6 (CMTM6) expression. Specifically, disclosed are a gene therapy vector encoding a gene sequence targeting CMTM6 and a derivative thereof, a gene sequence encoded by a vector, a preparation method, and a use of a vector alone and in combination with other drugs in treating tumors. These gene therapy vectors comprise adeno-associated viruses and lentiviruses, etc., can inhibit the expression of CMTM6 in tumor tissues, can effectively inhibit the in-vivo growth of mouse and human colorectal cancer, melanoma, liver cancer, breast cancer, non-small cell lung cancer and the like by improving the tumor immunosuppression microenvironment, exhibit a strong anti-tumor effect in combination with immune checkpoint antibodies, chemotherapeutic drugs, immunoagonistic drugs, and metabolic regulation drugs, and have significant efficacy on PD-L1-deficient tumors and immune checkpoint antibody drug-resistant tumors.